It is made available under a CC-BY 4.0 International license .

- 1 A New Advanced Osteoarthritis Treatment Utilizing Modified Mesenchymal Stem
- 2 Cells: Arthroscopic Guided Intra-Articular Intervention Approach a Systematic Review
- 3 and Meta-Analysis

4

- 5 Kevin Christian Tjandra^{1; 3},
- 6 Robin Novriansyah^{2; 3},
- 7 Ardiyana $Ar^{1;3}$,
- 8 Nurul Azizah Dian Rahmawati^{1; 3},
- 9 I Nyoman Sebastian Sudiasa^{1; 3},
- 10 Ismail Hadisoebroto Dilogo^{4; 5; 6}
- ¹Departement of Medicine, Faculty of Medicine, Universitas Diponegoro, Semarang,
 Indonesia
- ¹³ ²Department of Surgery, Faculty of Medicine, Universitas Diopnegoro, Semarang, Indonesia
- ¹⁴ ³Kariadi General Hospital, Semarang, Indonesia
- ⁴Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central
- 16 Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
- ¹⁷ Stem Cell and Tissue Engineering Research Cluster Indonesian Medical Education and
- 18 Research Institute (IMERI) Universitas Indonesia, Jakarta, Indonesia

It is made available under a CC-BY	4.0 International license
------------------------------------	---------------------------

- ⁶Department of Orthopaedic and Traumatology, Cipto Mangunkusumo General Hospital,
- 20 Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
- 21

22 Correspondence:

23 Ismail Hadisoebroto Dilogo, MD, PhD, Stem Cell Medical Technology Integrated Service

24 Unit, Cipto Mangunkusumo Central Hospital, Faculty of Medicine Universitas Indonesia,

25 CMU 2 Building, Kimia Street No. 40, Jakarta, Indonesia.

26 Email: ismailortho@gmail.com

- 27
- 28 Abstract

29 **Background:** The mesenchymal stem cells (MSCs) is able to regenerate the cartilage defect 30 caused by osteoarthritis (OA) to prevent permanent disability. Its efficacy may be even greater in combination with platelet-rich plasma (PRP) and hyaluronic acid (HA). Thus, this 31 32 systematic review aimed to investigate the efficacy of MSCs in combination with PRP and adjusted doses of HA, the best source of MSCs, and the optimal number of applied MSCs to 33 34 treat osteoarthritis as a cartilage regenerative agent. Method: The sources included were 35 original articles published from 2013 until 2023 from 4 databases (Pubmed, Springerlink, 36 ScienceDirect, and Google Scholar). Studies included were original research of clinical 37 trials or randomized controlled trials. Irrelevant studies were excluded. Then, the ROB-2 38 taken was used to assess bias. The result was constructed with PICOS criteria within the 39 table created in the Google spreadsheet. MRI score, VAS score, Lysholm score, Cartilage 40 volume, size of cartilage defect, Knee Society Clinical Rating System Score (KSS), and

It is made available under a CC-BY 4.0 International license .

41 WOMAC index to evaluate treatment's effication outcomes were analyzed by Revman 5.4. 42 This systematic review followed the PRISMA guidelines. **Result:** nine studies were included in the final screening. The meta-analysis showed a significant (P < 0.00001) elevation of 43 Lysholm score with a pooled mean difference (MD) of (17.89) (95% CI: 16.01, 19.77: $I^2 =$ 44 0%, P = 0.56); a significant reduction (P < 0.00001) of VAS score with a pooled MD of (-45 2.62) (95% CI: -2.83, -2.41; $I^2 = 99\%$, P < 0.00001); Knee society clinical rating system 46 score (KSS) evaluation also showed significant elevation (P < 0.00001) with mean polled 47 (29.59) (95% CI: 27.66, 31.52; $I^2 = 95\%$, P< 0.0001); and significantly reduction (P< 48 (0.00001) of WOMAC score occurred as pooled MD of (-12.38) $(95\% CI: -13.75, -11.01; I^2 = 1.000000)$ 49 99%, P < 0.0001). Conclusions: Arthroscopic guided high- dose subchondral application of 50 51 primary cultured synovial mesenchymal stem cells in popliteal platelet-rich plasma media 52 combined with hyaluronic acid effectively regenerate cartilage defect and increase clinical 53 outcomes in the early stage of osteoarthritis. 54

55 Keywords: Synovial mesenchymal stem cells, Osteoarthritis, Intra-articular intervention

56 Level of Evidence: Therapeutic Level I.

57 Introduction

Osteoarthritis is a chronic inflammatory joint disease due to the degradation of the cartilage that causes joint pain and limitation in movement [1]. Over three decades, the global prevalence of OA increased by 113.25% from 1990-2019 with an estimated 527.81 million people [2]. The pathogenesis of OA is complex due to the multifactorial factors that can influence the occurrence and progression of the disease, including genetic, cellular, biochemical, and immunological. However, the main pathogenesis pathway that worsens the

It is made available under a CC-BY 4.0 International license .

OA condition is the calcification of the cartilage defect. Thus, cartilage repair may prevent
the progression of osteoarthritis [3][4].

The pharmacological conservative therapy does not provide significant benefits and the side effects that can arise also need to be considered in its application [5]. Furthermore, pharmacotherapy itself is not able to solve the main problem of OA, cartilage damage. Surgical techniques such as total knee replacement can be performed but the risk of persistent pain or loss of joint function reaches 20% [6]. Thus, less invasive procedure with promising result is needed to treat OA.

72 Mesenchymal stem cells (MSCs) as the regenerative agent is one of the solution of knee OA 73 treatment because of its ability to regenerate cartilage defect [7]. Among various MSC 74 sources, synovial MSC is a promising cell source for cartilage repair. Synovial MSCs have 75 superior chondrogenic ability compared to MSCs from other tissues [8]. Synovial tissue has 76 the greatest potential for differentiation into chondrogenic cells and proliferation. The 77 synovium is a thin membrane that covers the inside of the joint and has a high regenerative 78 activity. According to previous studies, the amount of MSCs in synovial fluid is increased in 79 knees with OA that proving its regeneration activity [9]. Transplantation of large numbers of 80 synovial MSCs into injured cartilage tissue can enhance the natural healing process. From 81 previous studies, synovial MSCs were transplanted arthroscopically and led patients to return 82 to daily life and sports activities earlier than patients with invasive surgery [8]. Therefore, this 83 systematic review aimed to investigate the efficacy of MSCs in combination with PRP and 84 adjusted doses of HA, the best source of MSCs, and the optimal number of applied MSCs to 85 treat osteoarthritis as a cartilage regenerative agent.

86

It is made available under a CC-BY 4.0 International license .

87 Material and Method

88 <u>Registration</u>

89 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were

- 90 used for this systematic review [10]. On August 8, 2023, this systematic review and meta-
- 91 analysis was registered to the Open Science Framework (OSF).

92 <u>Eligibility criteria</u>

93 From 2013 until 2023 (the last date for which a search was conducted was 22 May 2023), we 94 have included original content. The study included original research publications that met the 95 inclusion criteria for autologous clinical trials and randomized controlled trials (RCT). 96 Technical reports, editor answers, narrative reviews, systematic reviews, meta-analyses, non-97 comparative research, in silico studies, in vitro studies, in vivo studies, scientific posters, 98 study protocols, and conference abstracts were all discarded. Non-English, non-full-text, and 99 unrelated papers that were not related to the application of MSCs to treat knee osteoarthritis 100 were also removed. The desired PICO criteria of the selected articles including i) patient with 101 osteoarthritis or cartilage damage; ii) Intervention of intra-articular intervention or 102 arthroscopic guided MSCs application; iii) Comparison, standard care without synovial stem 103 cell application (placebo); and iv) Outcomes, treatment's evaluation of AMADEUS MRI 104 score for cartilage defect, VAS score, Lysholm score, Cartilage volume, size of cartilage 105 defect, Knee Society Clinical Rating System Score (KSS), and WOMAC index.

106 *Outcome measure*

The efficacy evaluation of the therapy was then assessed by several outcomes including MRI
score, VAS score, Lysholm score, Cartilage volume, size of cartilage defect, Knee Society
Clinical Rating System Score (KSS), and WOMAC index. The AMADEUS MRI score for

It is made available under a CC-BY 4.0 International license .

110 cartilage defects was assessed before and after treatment to know the cartilage regeneration; 111 the VAS score was used to assess the clinical pain before and after treatment; the Lysholm 112 score was used to assess the symptom of disability; then the WOMAC index has a role to 113 assess the severity clinical problem in osteoarthritis patients; and KSS is used to evaluate rate 114 the knee and patient's functional abilities.

115

116 <u>Index Test</u>

Studies that provided data on the application and evaluations of bone membrane mesenchymal stem cells in osteoarthritis are included in this systematic review and metaanalysis.

120

121 <u>Reference Standard</u>

Reference standards are professional research using randomized controlled clinical studies
(RCT) or clinical trials to assess the transition of mesenchymal stem cells in osteoarthritis
outcomes.

125

126 *Data Sources and Search*

Research for this study was gathered through Pubmed, Springerlink, Google Scholar, and Science Direct database searches. The database was searched from its establishment until 22 May 2023 during 10-year periods prior to this review. The Boolean operator was utilized among the Medical Subject Headings (MeSH) keywords determined from the national institute of Health (NIH) National Library of medicine browser. In **Table 1**, the keywords used in each database are displayed. The studies are kept using Mendeley Group Reference Manager in the authors' library. Clinical trial and randomized controlled trial type articles

It is made available under a CC-BY 4.0 International license .

were used as a filter in the Pubmed database, the content-type article was used as the Springer database filter, the research article type was used for the Science Direct database filter, and any type of article was used in Google Scholar. A total of 5,101 studies were found in the database (4478 from Springerlink, 521 from Pubmed, 70 from Google Scholar, and 32 from Science Direct). 561 studies were imported to the Mendeley Group Reference Manager in the authors' library after the aforementioned criteria were added, and this was done before the selection procedure.

141

142 **Table 1.** Keyword Used in Literature Searching

143

Database	Keywords
Pubmed	Osteoarthritis and Synovial Membrane and Stem Cell
Springerlink	
Science Direct	
Google Scholar	

144

145 <u>Selection process</u>

Four independent reviewers (KCT, AA, NADR, and INSS) and one validator (RN) combined the outcomes from four databases after applying the search keywords indicated in Table 1. After that, they conducted a complete text and abstract screening to exclude non-clinical trial and non-randomized controlled trial papers while keeping the pertinent ones. 534 studies were eliminated from this process because they did not provide sufficient data to answer the

It is made available under a CC-BY 4.0 International license .

151 research question (application and evaluations of MSCs in osteoarthritis) and because their 152 study designs did not meet the criteria for inclusion (clinical trial and randomized controlled 153 trial) and 16 studies were removed due to duplication. The retrieval of the complete text for 154 the remaining 11 studies were then tested. Only 10 full text articles could be obtained as a 155 result. Then, utilizing the title, year of publication, and DOIs, one publication was eliminated 156 due to irrelevant outcome of interest. Using the Cochrane Risk of Bias 2 For Randomized Trials (ROB-2) tool, the nine included studies were evaluated for eligibility. All nine of the 157 158 listed studies from this process passed the evaluation bias check. The PRISMA flow chart 159 contained records of the research selection procedures.

160

161 *Data collection process*

After the final screening, the pertinent information from studies is retrieved and entered into a Google Spreadsheet. Recorded datas in characteristic table consists of author, year, country, study design, sample size, gender, mean age, intervention name, comparison, and outcome consisting of the AMADEUS MRI score for cartilage defect, VAS score, WOMAC Index, Cartilage volume, size of cartilage defect, Knee Society Clinical Rating System Score (KSS).

167

168 <u>Study Risk of Bias assessment (Qualitative Synthesis)</u>

Risk-of-bias tool used to assess the bias of included studies was the Cochrane risk-of-bias tool for randomized trials (RoB-2) which can be accessed in (https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-

172 randomized-trials), was used by five independent reviewers (KCT, RN, AA, NADR, INSS,

173 and IHD). Any disagreements regarding the bias assessment were discussed further and

settled between the 5 reviewers. Papers deemed with a high risk of bias will be removed from

It is made available under a CC-BY 4.0 International license .

the systematic review to preserve the validity of included data in the current study as shown

176 in.

177

178 <u>Reporting bias asseessment</u>

179 As the result of ROB-2 assessment bias conducted by KCT, AA, NADR, INSS, and RN, all

nine included articles did not show any critical overall bias as mentioned in Figure 1 so no

181 article was removed at this stage.

182

183 *Quantitative Synthesis*

Outcomes were presented in the form of mean difference (MD) and standard deviation (SD) with a confidence interval (CI) of 95% in the characteristic table. Meta-analysis was used with a fixed-effect model (FEM) when the included studies were considered homogenous (low variability in studies' results or variation due to random error), which was indicated by an I^2 value of less than 40%. Otherwise, we used a random-effect model (REM). The pooled mean difference estimate was presented in a forest plot.

190

191 **Result**

192 <u>Study Selection</u>

A literature search utilizing Springerlink, Pubmed, Google Scholar, and ScienceDirect resulted in 5,101 papers overall. Automation approaches from each database were used to exclude non-clinical trials and non-randomized controlled trial research, which resulted in the

It is made available under a CC-BY 4.0 International license .

196 elimination of 4,540 articles. After writers checked each and every article for relevancy and 197 duplication starting with the title and abstract, 534 irrelevant subjects and 16 duplicate 198 articles were eliminated. The inability to get the complete text document caused 1 unretrieved 199 item to be eliminated. Then, 1 irrelevant outcome of interest research papers were eliminated. 200 The full texts of nine articles were subsequently acquired. Last but not least, the author 201 determined each study's eligibility, and all nine studies met the requirements. This systematic 202 review and meta-analysis include nine articles. The flow chart for the PRISMA diagram 203 illustrating our research selection procedure is shown in Figure 1.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only



204

It is made available under a CC-BY 4.0 International license .

Figure 1. PRISMA 2020 flow diagram.

206 <u>Study Characteristics</u>

- 207 The nine studies that made up this systematic review comprised a total of 315 participants.
- 208 Each four studies were conducted in different countries. Studies were carried out in Japan,
- 209 South Korea, France, China, USA, Iran, Singapore, and Spain. The complete study
- 210 characteristics, including the PICO of each study, are stated in **Table 2**.

211 <u>Risk of Bias in Studies</u>

Each clinical trial and randomized controlled trial study underwent a thorough assessment of its quality using the ROB-2 risk-of-bias method. In nine of the investigations, there were 3 studies identified as a study with some concern of bias due to unclear randomization process between the allocation of intervention and control group. An overview of the bias risk assessment is shown in Figure 2.

Study ID	Experimental	Comparator	Outcome	Weight	<u>D1</u>	DZ	D3	D4	D5	Overall		
Sekiya, et al; 2015	NA	NA	NA	1	1	•	•	÷	1		+	Low risk
Hyunchul C, et al; 2014	NA	NA	NA	1	1	•		•	•		1	Some concerns
Hernigou P, et al; 2020	NA	NA	NA	1	÷	•	+	+	•	$\overline{\bullet}$		High risk
Xu z, et al; 2020	NA	NA	NA	1	1	•	•		•			
Garza JR, et al; 2020	NA	NA	NA	1	÷	•	•	•	•	•	D1	Randomisation process
Emededin M, et al; 2012	NA	NA	NA	1	1		•	•	1		D2	Deviations from the intended interventions
Hyunchul C, et al; 2017	NA	NA	NA	1	•	•	•	•	•	•	D3	Missing outcome data
Wong KL, et al; 2013	NA	NA	NA	1	٠	•	•	•	•	•	D4	Measurement of the outcome
Espinosa JML, et al; 2016	NA	NA	NA	1	•	•	•	•	•	•	D5	Selection of the reported result

218 **Figure 2.** Risk of Bias Assessment

219 <u>Study Result Summaries</u>

217

The journal selection method that has been carried out produced four studies that were used in the systematic review and meta-analysis process. The nine studies were conducted by

Sekiya et al. (2015), Hyunchul C et al. (2014), Hernigou et al. (2020) Xu Z	Z et al.	(2020)
---	----------	--------

- Garza JR et al. (2020), Emededin M et al. (2012), Hyunchul C et al. (2017), Wong KL et al.
- (2013), Espinosa JML, et al. (2016). Brief profiles of the nine studies are shown in Table 2.

225 <u>Lysholm score</u>

226 The disability symptoms caused by OA were assessed based on Lysholm's score in the 227 questionnaires of the respective standardized tools. A meta-analysis of two studies assessed 228 the efficacy of OA synovial fluid stem cells in relieving disability symptoms in the pre-229 intervention and post-intervention groups. The forest plot in Figure 3 depicts a significant 230 effect (P < 0.00001) with a pooled mean difference (MD) of (17.89) (95% CI: 16.01, 19.77). 231 This result indicates that synovial fluid stem cell was found to decrease Lysholm score in OA 232 patients significantly. The forest plot also showed heterogeneity was found (I2 = 0%; P 233 <0.00001) for the efficacy of synovial fluid stem cells in relieving the disability symptoms in 234 OA patients.

Study or Subgroup Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI IV, Fixed, 95% CI Sekiya I, et al; 2015 95 3 10 76 6 10 20.4% 19.00 [14.84, 23.16] Total Total Total Mean Sekiya I, et al; 2020 (80 2.8 48 62.4 6.3 40 79.6% 17.60 [15.49, 19.71] Total Total		Inter	venti	on	LC	ontro	1		Mean Difference	Mean D	ifference
Sekiya I, et al; 2015 95 3 10 76 6 10 20.4% 19.00 [14.84, 23.16] Xu Z, et al; 2020 (80 2.8 48 62.4 6.3 40 79.6% 17.60 [15.49, 19.71]	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed	l, 95% CI
Xu Z, et al; 2020 (80 2.8 48 62.4 6.3 40 79.6% 17.60 [15.49, 19.71]	Sekiya I, et al; 2015	95	3	10	76	6	10	20.4%	19.00 [14.84, 23.16]		-
	Xu Z, et al; 2020 (80	2.8	48	62.4	6.3	40	79.6%	17.60 [15.49, 19.71]		
Iotal (95% Cl) 58 50 100.0% 17.89 [16.01, 19.77]	Total (95% CI)			58			50	100.0%	17.89 [16.01, 19.77]		•

235

Figure 3. Forest plot of Lysholm score between intervention vs control group

237 <u>Visual Analog Scale (VAS)</u>

Clinical pain experienced by OA patients is assessed with VAS scores which are shown in Figure 4. A meta-analysis included three studies that analyzed the efficacy of synovial fluid stem cells in reducing clinical pain in OA patients. The forest plot showed a significant effect (P < 0.00001) with a pooled MD of -2.62 (95% CI: -2.83, -2.41). The pooled MD shows that

It is made available under a CC-BY 4.0 International license .

- 242 mesenchymal stem cell is significantly effective in reducing clinical pain in OA patients.
- Heterogeneity was found (I2 = 0%; P = <0.00001).

	Inte	rventi	on	C	ontrol			Mean Difference		1	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI			V, Fixed, 95% CI		
Emededin M, et al; 2012	1.89	0.3	6	2.91	0.37	6	29.9%	-1.02 [-1.40, -0.64]					
Hyunchul C, et al; 2017	3.33	0.78	12	7.96	0.22	12	20.7%	-4.63 [-5.09, -4.17]					
Xu Z, et al; 2020 (2.1	0.8	48	4.85	0.62	40	49.4%	-2.75 [-3.05, -2.45]			-		
Total (95% CI)			66			58	100.0%	-2.62 [-2.83, -2.41]					
Heterogeneity: Chi ² = 142	.25, df =	= 2 (P	< 0.00	001); l ²	= 999	6			100	to		50	100
Test for overall effect: Z =	24.63 (P < 0.	00001)						-100	-50 Favours (experi	mental] Favours [control]	100

Figure 4. Forest plot of VAS score between intervention vs control group

246 <u>Knee Society Clinical Rating System Score (KSS)</u>

- 247 Knee function and ability in OA patients is assessed with KSS scores as shown in Figure 5.
- The forest plot using KSS showed a significant effect (P < 0.00001) with a pooled MD of
- 249 29.59 (95% CI: 27.66, 31.52). The pooled MD shows mesenchymal stem cells significantly
- improved knee function and ability. Heterogeneity was found (I2 = 95%; P < 0.00001).

	Inter	venti	on	C	ontro	1		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Hernigou P, et al; 2020	79.3	12	60	55	18	60	12.4%	24.30 [18.83, 29.77]	+
Hyunchul C, et al; 2014	71	4.4	12	47.2	2.6	12	44.5%	23.80 [20.91, 26.69]	
Hyunchul C, et al; 2017	84.3	4.5	12	47.2	2.6	12	43.1%	37.10 [34.16, 40.04]	
Total (95% CI)			84			84	100.0%	29.59 [27.66, 31.52]	•
Heterogeneity: Chi ² = 44.	.05, df =	2 (P	< 0.00	001); 1	2 = 9	5%			
Test for overall effect: Z =	= 30.06	(P < (0.0000	1)					Favours [experimental] Favours [control]

Figure 5. Forest plot of KSS score between intervention and control group.

253 <u>WOMAC Score</u>

244

251

- 254 Symptoms in OA patients is assessed with WOMAC score as shown in Figure 6. The forest
- plot analyzing WOMAC score showed a significant effect (P < 0.00001) with a pooled MD
- of -12.38 (95% CI: -13.75, -11.01). The pooled MD shows mesenchymal stem cells
- significantly relieve symptoms in OA patients. Heterogeneity was found (I2 = 99%; P <
- 258 0.00001).

It is made available under a CC-BY 4.0 International license .

	Inte	rventi	on	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Emededin M, et al; 2012	11.6	24	6	57.33	33	6	0.2%	-45.73 [-78.38, -13.08]	
Espinosa JML, et al; 2016	16.5	1.22	10	13.5	8.33	10	6.9%	3.00 [-2.22, 8.22]	
Garza JR, et al; 2020	13.2	3.6	12	49.3	4.98	12	15.5%	-36.10 [-39.58, -32.62]	+
Hyunchul C, et al; 2014	32.8	6.2	12	54.2	5.2	12	8.9%	-21.40 [-25.98, -16.82]	+
Hyunchul C, et al; 2017	16	4.4	12	54.2	5.2	12	12.6%	-38.20 [-42.05, -34.35]	-
Xu Z, et al; 2020 (97.9	5.3	48	98.2	3.4	40	55.8%	-0.30 [-2.13, 1.53]	•
Total (95% CI)			100			92	100.0%	-12.38 [-13.75, -11.01]	•
Heterogeneity: Chi ² = 570.	43, df =	5 (P -	< 0.000	001); I ²	= 99%				100 10
Test for overall effect: Z =	17.72 (F	P < 0.0	00001)						Favours [experimental] Favours [co

259

Figure 6. Forest plot of WOMAC score between intervention and control group.

261 **Discussion**

262 Synovial Mesenchymal Stem Cell

263 Synovial Mesenchymal Stem Cells (Sy-MSCs) originate from the mesenchyme, 264 which is an embryonic connective tissue that gives rise to various types of cells, including 265 bone, cartilage, and adipose tissue. Synovial MSCs have the ability to self-renew and 266 differentiate into several types of cells from the mesenchymal lineage, including osteoblasts 267 (bone cells), synovial (cartilage cells), and adipocytes (fat cells) [11]. They also exhibit 268 immunomodulatory properties, meaning they can regulate the immune response. Synovial 269 MSCs can be isolated from synovial fluid or the synovial membrane/tissue of joints such as 270 the knee, hip, or shoulder. Various methods, including aspiration or biopsy, can be used to 271 obtain these cells [12].

Synovial MSCs have garnered significant interest in regenerative medicine and tissue engineering due to their ability to differentiate into different cell types [13]. It has been shown that Sy-MSCs had a greater proliferation capacity and stronger chondrogenic potential than Bone Marrow-MSCs and Adipose Tissue-MSCs, as well as less hypertrophic differentiation than bone Bone Marrow-MSCs. In addition, pellet cultures were significantly larger from Sy-MSC than Bone Marrow-MSCs in patient-matched comparisons. They hold

It is made available under a CC-BY 4.0 International license .

promise for the repair and regeneration of damaged or diseased joint tissues, such as cartilage
and bone. They are being explored as potential treatments for conditions such as
osteoarthritis, rheumatoid arthritis, and joint injuries [14].

281 Synovial MSCs play an important role in the pathophysiology and treatment of osteoarthritis (OA). In osteoarthritis, the synovial membrane undergoes changes, including 282 283 inflammation and hyperplasia [15]. Synovial MSCs participate in the repair and maintenance 284 of joint tissues, including articular cartilage. However, in OA, the regenerative capacity of 285 synovial MSCs is often impaired due to factors such as aging, inflammation, and abnormal 286 joint microenvironment. Synovial MSCs have chondrogenic potential, meaning they can 287 differentiate into chondrocyte-like cells responsible for producing and maintaining the 288 cartilage matrix [16][17][18].

Synovial MSCs hold promise for the treatment of OA. They can be isolated from synovial fluid or the synovial membrane through minimally invasive procedures [19]. These cells can be expanded in the laboratory and then transplanted back into the joint to promote tissue repair and regeneration.

293 Application of Synovial Stem Cell in Treating Osteoarthritis

Osteoarthritis may develop as a result of articular cartilage injuries, which are a common clinical issue. Despite the variety of surgical intervention techniques, each has disadvantages of its own: Bone marrow stimulation results in poor structural quality of the repaired cartilage, donor site morbidity in mosaicplasty, and loss of the chondrogenic phenotype of expanded chondrocytes in autologous chondrocyte implantation [20]. One potential method for enhancing cartilage injury repair is stem cell therapy. Mesenchymal stem cells (MSCs),

It is made available under a CC-BY 4.0 International license .

which can be isolated from various mesenchymal tissues, especially synovial membranes areone of the potential therapeutic cells.

302 The potential of synovial MSCs can be maximized by combining with other intraarticular 303 regeneration agents, including, Platelet-Rich Plasma and hyaluronic acid [21]. This 304 combination might be a great solution to treat cartilage damage in Osteoarthritis and prevent 305 the overuse of hyaluronic acid that fastens the OA disease progression. A small amount of 306 hyaluronic acid intraarticular application is able to stimulate cartilage regeneration. However, 307 this small amount of HA is not enough to stop the disease progression, but the more 308 hyaluronic acid is used the more VEGF production occurs. The high amount of VEGF will 309 calcify the cartilage and convert it into osteocytes which worsen osteoarthritis [22].

Among all 4 Kellgern Lawrence classifications, this non-operative treatment is useful in OA grades 1 - 3. The earlier stage the greater outcome will be obtained [23]. It is because of this treatment strategy, that Modified Synovial Mesenchymal Stem Cells act as a cartilage regenerative agent that prevents further OA progression [8].

314 Cellaid1 (JMS Co Ltd, Hiroshima, Japan), a closed-bag system for serum isolation, was used 315 to collect 300 mL of whole blood from the patient's knee intraarticular, obtained by 316 microfracture; fat pad severe; and suprapatellar pouch severe, one or two days prior to the 317 harvest of synovial tissue. The popliteal vein is preferred due to its protein-rich plasma or 318 autologous serum being suitable for the synovial stem cell culture process. The system 319 consists of a blood donation bag filled with glass beads that, over 30 minutes of gentle 320 mixing, activate platelets and remove fibrin from whole blood. The serum was isolated and 321 heat-inactivated at 56° C for 30 minutes, following centrifugation at 2000 g for 7 minutes.

It is made available under a CC-BY 4.0 International license .

Before use, the serum was stored at 4° C after filtering through a 0.45-lm nylon filter from
Becton Dickinson, Franklin Lakes, New Jersey, USA [24].

The related Patients then underwent arthroscopy under the effects of local anesthesia containing 20 mL of 1% xylocaine. The synovium with sub synovial tissue on the femur at the suprapatellar pouch was then harvested with a pituitary rongeur under arthroscopic supervision while the patient was under intravenous anesthesia with 0.1 g sodium pentothal. After the synovial MSCs were harvested, patients were able to leave the hospital during the culture period [8].

330 The harvested synovial MSCs then digested using a solution of 5 mg Liberace in 5 ml Hanks' 331 balanced salt solution for 3 hours. Then the result was filtered through a 70-µm nylon filter to 332 obtain the target synovial MSCs. The cells were grown in a-MEM from Invitrogen, which 333 contained 10% autologous human serum, 100 units/mL of penicillin, 100 µg/mL of 334 streptomycin, and 250 ng/mL of amphotericin B. In total, 50 dishes were examined on day 12 335 to look for bacteria, endotoxins in the medium, mycoplasma, and viruses in the cells. 336 Chocolate agar was utilized for bacterial testing. A Toxicolor1 LS-50M kit (Seikagaku 337 Corporation, Tokyo, Japan) was used for endotoxin testing. A multiplex PCR system created 338 by our team was utilized for testing for mycoplasma and viruses [6]. This system detected 17 339 different virus types and 142 different mycoplasma types. Chromosomal testing was also 340 conducted using one dish [25][26].

After no harmful contamination was confirmed, the synovial MSCs were harvested at day 14 using TrypLE at 37oC for 5 minutes. Primary synovial MSCs were suspended in 0.5 mL of acetate Ringer's solution 30 minutes prior to transplantation. 47 million \pm 21 million transplanted cells (mean \pm SD) were used [27].

It is made available under a CC-BY 4.0 International license .

For the transplant, the patient was positioned with the cartilage defect facing upward, and using an 18-gauge needle and a 1-mL syringe, a suspension of synovial MSCs in 0.5 mL of acetate Ringer's solution was injected into the defect under arthroscopic supervision. The defect was then held in the upward position for 10 minutes with the applied suspension. After 10 minutes, the additional 0.25 ml might be added to the cartilage defect in order to reduce synovial inflammation and reduce pain after the procedure [28].

Following surgery, all patients began knee ROM exercises. After two weeks and six weeks, they could bear total weight. There was no use of specialized machinery like a continuous passive motion machine. Generally, low-impact activities could begin at three months and high-impact activities at six. Then, the outcome evaluation was assessed using MRI, Lysholm score and Visual Analog Scale (VAS).

356

357 Effication of MSCs in Treating Osteoarthritis

358 In recent years, the potential use of mesenchymal stem cells as a therapeutic approach for OA 359 has gained significant attention. Compared to conventional bone marrow MSCs, Synovial 360 mesenchymal stem cell (SFCs) has more efficacy as proven in the study conducted by 361 Sekiya, et al. (2015) [8]. It's because synovial fluid cells have more similarity in synovial 362 environment than other sources of cells. Thus, it can exhibit multipotency where each cell can 363 differentiate into various cell types including chondrocytes, which are crucial for the 364 maintenance and repair of cartilage. The regenerative properties of SFSCs are important in a 365 joint inflammation disease such as osteoarthritis. A study by Kim et al. (2019) demonstrated 366 that SFSCs derived from OA patients could differentiate into chondrogenic lineage cells and 367 promote cartilage matrix formation [29]. Moreover, another study by Qiu et al. (2021)

It is made available under a CC-BY 4.0 International license .

reported that SFSCs combined with hyaluronic acid injections resulted in improved cartilage regeneration and enhanced functional outcomes in a rabbit model of OA [30]. Then, the efficacy of this treatment can be maximized by the application of appropriate high-dose MSCs (1 x 10^8 cells) with subchondral technique compared to intra-articular injection as proven by a study conducted by Hernigou P, et al. (2020)[31].

However, studies exploring the efficacy of SFSCs in human trials are still relatively limited.
A phase I/II clinical trial conducted by Jo et al. (2019) involved intra-articular injection of
SFSCs in patients with knee OA [32].

This study reported significant improvements in pain, function, and cartilage quality, demonstrating the potential of MSCs as a new treatment modality for OA. Studies conducted by Sekiya et al. (2015) and Xu, et al. (2020) has proven elevation of the Lysholm score va which assesses disability in OA patients proved to be statistically significant (P <0.001) increased by polled MD (17.89) [95% CI:16.01, 19.77] compared to the control group [8] [33].

382 In addition, MSCs were also proven to be significantly effective in reducing VAS scores as 383 proven by studies conducted by Emededin M, et al. (2012), Hyunchul, et al. (2017), and Xu 384 Z, et al. (2020) showed the statistical effectiveness of Intra-articular Injection of Autologous 385 MSCs (P <0.00001) with pooled MD (-2.62) (95% CI: -2.83, -2.41) [34] [35] [33]. Proven by 386 MRI images, post-injection cartilage thickness increased in three of the six patients. Xu et al. 387 (2020) showed that the efficacy of intra-articular platelet-rich plasma (PRP) SFSC would 388 increase when combined with hyaluronic acid and (PRP) as demonstrated by a significant 389 reduction in VAS scores in the PRP+HA group at 24 months afterward. injection, PRP+HA 390 was more effective than HA and PRP alone in relieving pain (P = 0.0001) [33]. In addition,

It is made available under a CC-BY 4.0 International license .

significant improvements were also observed in the PRP+HA group after 1, 6, 12, and 24 months (P < 0.0001).

393 MSCs can also improve the WOMAC index which assesses the severity of clinical problems 394 in osteoarthritis patients. The results of the study by Emededin, et al. (2012), Espinosa, et al. 395 (2016), Garza, et al. (2020), Hyunchul, et al. (2014), Hyunchul, et al. (2017), and Xu, et al. 396 (2020) showed a clinically meaningful reduction of WOMAC score as much pooled MD (-397 12.38) (95% CI: -13.75, -11.01) [34][36][37][38][35]. In addition, KSS function score evaluation from Hernigou, et al. (2020), Hyunchul, et al. (2014), and Hyunchul, et al. (2017) 398 399 increased significantly from as much pooled MD (29.59) (95% CI: 27.66, 31.52) 400 [31][35][38].

401

402 Strength and Limitation

This study is the first systematic review and meta-analysis that assessed the efficacy of synovial fluid stem cell in treating osteoarthritis. This study also included studies from various countries showing this therapy's universal applicability. Although this study also has several limitations such as the limited number of included studies.

407

408 Conclusion

409 Arthroscopic guided injection of primary cultured synovial mesenchymal stem cells in 410 popliteal platelet-rich plasma media combined with hyaluronic acid is effectively regenerate 411 cartilage defect in the early stage of osteoarthritis and reduce synovial inflammation that may

It is made available under a CC-BY 4.0 International license .

- 412 cause knee pain. Synovial mesenchymal stem cells have also been proven to not cause any
- 413 side effects in osteoarthritis patients.
- 414

415 **Recommendation**

416 More studies need to be conducted to further evaluate the duration and efficacy of the

417 synovial mesenchymal stem cell as a novel therapy for osteoarthritis.

418

419 Data availability

- 420 Underlying data
- 421 All data underlying the results are available as part of the article and no additional source data
- 422 are required.

423 Reporting guidelines

- 424 Mendeley Data: A New Advanced Osteoarthritis Treatment Utilizing Modified Synovial
- 425 Mesenchymal Stem Cells: Arthroscopic Guided Intra-Articular Intervention Approach a
- 426 Systematic Review and Meta-Analysis. doi: 10.17632/zn8t3gks5g. .
- 427 Data are available under the terms of the Creative Commons Attribution 4.0 International
- 428 <u>license</u> (CC-BY 4.0).

429

430 Funding

431 The author(s) declared no funding information available.

432

It is made available under a CC-BY 4.0 International license .

433 Competing interests

434 No competing interests were disclosed.

435

436 **Grant information**

437 The author(s) declared that no grants were involved in supporting this work.

438

439

440

441

It is made available under a CC-BY 4.0 International license .

442 **Reference**

443	1.	Miller A, Lutsky KF, Shearin J, Cantlon M, Wolfe S, Beredjiklian PK. Radiographic
444		Patterns of Radiocarpal and Midcarpal Arthritis. J Am Acad Orthop Surg Glob Res
445		Rev. 2017 Jun;1(3):e017.
446	2.	Long H, Liu Q, Yin H, Wang K, Diao N, Zhang Y, et al. Prevalence Trends of Site-
447		Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of
448		Disease Study 2019. Arthritis Rheumatol. 2022;74(7):1172-83.
449	3.	Dobson GP, Letson HL, Grant A, McEwen P, Hazratwala K, Wilkinson M, Morris JL.
450		Defining the osteoarthritis patient: back to the future. Osteoarthritis Cartilage. 2018
451		Aug;26(8):1003-1007.
452	4.	Stewart HL, Kawcak CE. The Importance of Subchondral Bone in the
453		Pathophysiology of Osteoarthritis. Front Vet Sci. 2018;5:178.
454	5.	Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and
455		therapy. Osteoarthr Cartil [Internet]. 2020;28(3):242-8. Available from:
456		https://doi.org/10.1016/j.joca.2020.01.002
457	6.	Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement:
458		prevalence, sensory qualities, and postoperative determinants. Pain. 2011;152(3):566-
459		572. doi:10.1016/j.pain.2010.11.023.
460	7.	Sergijenko A, Roelofs AJ, Riemen AHK, De Bari C. Bone marrow contribution to
461		synovial hyperplasia following joint surface injury. Arthritis Res Ther. 2016 Jul
462		13;18(1).
463	8.	Sekiya I, Muneta T, Horie M, Koga H. Arthroscopic Transplantation of Synovial Stem

It is made available under a CC-BY 4.0 International license .

- 464 Cells Improves Clinical Outcomes in Knees With Cartilage Defects. Clin Orthop Relat
- 465 Res. 2015 Jul 8;473(7):2316–26.
- 466 9. Sekiya I, Ojima M, Suzuki S, et al. Human mesenchymal stem cells in synovial fluid
- 467 increase in the knee with degenerated cartilage and osteoarthritis. J Orthop Res.
- 468 2012;30(6):943-949. doi:10.1002/jor.22029.
- 469 10. Tjandra, K. C., Novriansyah, R., Ar, A., Rahmawati, N. A. D., Sudiasa, I. N. S., &
- 470 Dilogo, I. H. (2023, August 5). A New Advanced Osteoarthritis Treatment Utilizing
- 471 Modified Synovial Mesenchymal Stem Cells: Arthroscopic Guided Intra-Articular
- 472 Intervention. https://doi.org/10.17605/OSF.IO/HS4RZ
- 473 11. Fellows CR, Matta C, Zakany R, Khan IM, Mobasheri A. Adipose, Bone Marrow and
- 474 Synovial Joint-Derived Mesenchymal Stem Cells for Cartilage Repair. Front Genet.

475 2016;7:213. Published 2016 Dec 20. doi:10.3389/fgene.2016.00213.

- 476 12. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis:
- 477 latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013;5(2):77-94.
- 478 doi:10.1177/1759720X12467868.
- 479 13. Fan J, Varshney RR, Ren L, Cai D, Wang DA. Synovium-derived mesenchymal stem

480 cells: a new cell source for musculoskeletal regeneration. Tissue Eng Part B Rev.

```
481 2009;15(1):75-86. doi:10.1089/ten.teb.2008.0586.
```

- 482 14. Li J, Long X, Ke J, Meng QG, Fang W. Zhonghua Kou Qiang Yi Xue Za Zhi.
 483 2005:40(5):362-364.
- Kong L, Zheng LZ, Qin L, Ho KKW. Role of mesenchymal stem cells in osteoarthritis
 treatment. J Orthop Translat. 2017;9:89-103. Published 2017 Apr 12.

It is made available under a CC-BY 4.0 International license .

487	16.	Pasculli RM, Kenyon CD, Berrigan WA, Mautner K, Hammond K, Jayaram P.
-----	-----	---

- 488 Mesenchymal stem cells for subchondral bone marrow lesions: From bench to bedside.
- 489 Bone Rep. 2022;17:101630. Published 2022 Oct 21. doi:10.1016/j.bonr.2022.101630.
- 490 17. Danišovič L, Varga I, Polák S. Growth factors and chondrogenic differentiation of

491 mesenchymal stem cells. Tissue Cell. 2012;44(2):69-73.

- doi:10.1016/j.tice.2011.11.005.
- 493 18. López-García L, Castro-Manrreza ME. TNF-α and IFN-γ Participate in Improving the
- 494 Immunoregulatory Capacity of Mesenchymal Stem/Stromal Cells: Importance of Cell-

495 Cell Contact and Extracellular Vesicles. Int J Mol Sci. 2021;22(17):9531. Published
496 2021 Sep 2.

- 497 19. Li N, Gao J, Mi L, Zhang G, Zhang L, Zhang N, et al. Synovial membrane
- 498 mesenchymal stem cells: past life, current situation, and application in bone and joint

diseases. Stem Cell Res Ther. 2020;11:1–12. Available from:

- 500 https://www.proquest.com/scholarly-j.
- 20. Mollon B, Kandel R, Chahal J, Theodoropoulos J. The clinical status of cartilage tissue

regeneration in humans. Osteoarthritis Cartilage. 2013;21(12):1824-1833.

503 doi:10.1016/j.joca.2013.08.024.

504 21. Tucker JD, Goetz LL, Duncan MB, Gilman JB, Elmore LW, Sell SA, et al.

- 505 Randomized, Placebo-Controlled Analysis of the Knee Synovial Environment
- 506Following Platelet-Rich Plasma Treatment for Knee Osteoarthritis. PM R. 2021 Jul
- 507 1;13(7):707–19.

It is made available under a CC-BY 4.0 International license .

508	22.	Bellini MR. Mitogen Inducible Gene-6 in Joint Health and Osteoarthritis [Internet].
509		ProQuest Dissertations and Theses. [Canada Ontario, CA]: The University of
510		Western Ontario (Canada) PP - Canada Ontario, CA; 2020. Available from:
511		https://www.proquest.com/dissertations-theses/mitogen-inducible-gene-6-joint-
512		health/docview/2717697236/se-2?accountid=49069
513	23.	Ghazi Zadeh L. Freeze-Dried Chitosan Platelet-Rich Plasma Mixtures for Knee
514		Meniscus Repair [Internet]. ProQuest Dissertations and Theses. [Canada Quebec,
515		CA]: Ecole Polytechnique, Montreal (Canada) PP - Canada Quebec, CA; 2018.
516		Available from: https://www.proquest.com/dissertations-theses/freeze-dried-chitosan-
517		platelet-rich-plasma/docview/2506679949/se-2?accountid=49069
518	24.	Nimura A, Muneta T, Koga H, et al. Increased proliferation of human synovial
519		mesenchymal stem cells with autologous human serum: comparisons with bone
520		marrow mesenchymal stem cells and with fetal bovine serum. Arthritis Rheum.
521		2008;58(2):501-510. doi:10.1.
522	25.	Nakamura K, Tsuji K, Mizuno M, Koga H, Muneta T, Sekiya I. Initial cell plating
523		density affects properties of human primary synovial mesenchymal stem cells. J
524		Orthop Res. 2019;37(6):1358-1367. doi:10.1002/jor.24112.
525	26.	Ito K, Shimizu N, Watanabe K, et al. Analysis of viral infection by multiplex
526		polymerase chain reaction assays in patients with liver dysfunction. Intern Med.
527		2013;52(2):201-211. doi:10.2169/internalmedicine.52.8206.
528	27.	Shimaya M, Muneta T, Ichinose S, Tsuji K, Sekiya I. Magnesium enhances adherence
529		and cartilage formation of synovial mesenchymal stem cells through integrins.
530		Osteoarthritis Cartilage. 2010;18(10):1300-1309. doi:10.1016/j.joca.2010.06.005.

It is made available under a	CC-BY 4	.0 International	license.
------------------------------	---------	------------------	----------

531 28. Koga H, Shimaya M, Muneta T, et al. Local adherent technique for transplanting 532 mesenchymal stem cells as a potential treatment of cartilage defect. Arthritis Res Ther. 533 2008;10(4):R84. doi:10.1186/ar2460. 534 29. Kim SH, Ha CW, Park YB, Nam E, Lee JE, Lee HJ. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of 535 536 the knee: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 537 2019;139. 538 30. Qiu M, Liu D, Fu Q. MiR-129-5p shuttled by human synovial mesenchymal stem cell-539 derived exosomes relieves IL-1^β induced osteoarthritis via targeting HMGB1. Life Sci 540 [Internet]. 2021;269(36):118987. Available from: 541 https://doi.org/10.1016/j.lfs.2020.118987 542 31. Hernigou P, Bouthors C, Bastard C, Flouzat Lachaniette CH, Rouard H, Dubory A. 543 Subchondral bone or intra-articular injection of bone marrow concentrate 544 mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee 545 arthroplasty at fift. 546 32. Saetan N, Honsawek S, Tanavalee A, et al. Relationship of plasma and synovial fluid 547 vascular endothelial growth factor with radiographic severity in primary knee 548 osteoarthritis. Int Orthop. 2014;38(5):1099-1104. doi:10.1007/s00264-013-2192-y. 549 33. Xu Z, He Z, Shu L, Li X, Ma M, Ye C. Intra-Articular Platelet-Rich Plasma Combined 550 With Hyaluronic Acid Injection for Knee Osteoarthritis Is Superior to Platelet-Rich 551 Plasma or Hyaluronic Acid Alone in Inhibiting Inflammation and Improving Pain and 552 Function [Internet]. Vol. 37, Arthroscopy - Journal of Arthroscopic and Related 553 Surgery. The Arthroscopy Association of North America; 2021. 903–915 p. Available

It is made available under a CC-BY 4.0 International license .

554		from: https://doi.org/10.1016/j.arthro.2020.10.013
555	34.	Emadedin M, Aghdami N, Taghiyar L, Fazeli R, Moghadasali R, Jahangir S, et al.
556		Intra-articular injection of autologous mesenchymal stem cells in six patients with
557		knee Osteoarthritis. Arch Iran Med. 2012;15(7):422-8.
558	35.	Jo CH, Chai JW, Jeong EC, Oh S, Shin JS, Shim H, et al. Intra-articular Injection of
559		Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A 2-Year
560		Follow-up Study. Am J Sports Med. 2017;45(12):2774-83.
561	36.	Lamo-Espinosa JM, Mora G, Blanco JF, Granero-Moltó F, Nuñez-Córdoba JM,
562		Sánchez-Echenique C, et al. Intra-articular injection of two different doses of
563		autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the
564		treatment of knee osteoarthritis: Multicenter randomized controlled clinical trial (phase
565		I/II). J Transl Med. 2016 Aug 26;14(1).
566	37.	Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical Efficacy of Intra-articular
567		Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-
568		Blinded Prospective Randomized Controlled Clinical Trial. Am J Sports Med.
569		2020;48(3):588-598
570	38.	Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for
571		the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial [published
572		correction appears in Stem Cells. 2017 Jun;35(6):1651-1652]. Stem Cells. 2014;
573		
574		



Figure 1. PRISMA 2020 flow diagram.

Work Rtvi 2013 mediate version posted December 21, 2023. Manuement of the preprint a whore the preprint a whole of the preprint a whole of the preprint a thread of the preprint and the p

It is made available under a CC-BY 4.0 International license .

Figure 2. Risk of Bias Assessment

medRxiv preprint doi: https://doi.org/10.1101/2023.12.18.23299488; this version posted December 21, 2023. The copyright holder for this preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2023.12.18.23299488; this version posted December 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 4. Forest plot of VAS score between Intervention VS control group It is made available under a CC-BY 4.0 International license.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.18.23299488; this version posted December 21, 2023. The copyright holder for this preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Trited Rxiv pleffrint doi:1/1/1/2023.12.18.23299488; this version posted December 21p 2023 to 1/2 per convergent to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure 6. Forest plot of WOMAC score between intervention and control group.